Updates on Pulmonary Hypertension
Open Access
- 10 February 2025
- journal article
- review article
- Published by Bentham Science Publishers Ltd. in The Open Respiratory Medicine Journal
- Vol. 19 (1)
Abstract
Pulmonary Arterial Hypertension (PAH) is an uncommon condition with high mortality. It is an underrecognized condition both in developing and developed countries, especially in developing countries, due to a lack of advanced healthcare facilities and resources for timely diagnosis. More than half of the individuals diagnosed with PAH live less than five years after diagnosis. In recent years, tremendous advancements have been made in diagnostic and therapeutic strategies for PAH patients. Phosphodiesterase 5 (PDE5) inhibitors, endothelin receptor antagonists, and prostacyclin inhibitors in various forms (oral, inhaled, intravenous, or subcutaneous) have been the cornerstone of medical treatment. Atrial septostomy, heart and lung transplant, balloon pulmonary angioplasty, and pulmonary thromboendarterectomy are existing therapeutic options currently available. There has been a continuous effort to introduce newer therapies to improve life expectancy and modify disease. Newer therapies have shown promising results but require future data to guarantee long-term safety and efficacy. We aim to discuss a few of these critical updates in the constantly evolving field of PAH.Keywords
This publication has 49 references indexed in Scilit:
- Navigating the Sotatercept landscape: A meta‐analysis of clinical outcomesClinical Cardiology, 2023
- Diagnosis and Treatment of Pulmonary Arterial HypertensionJAMA, 2022
- Tadalafil in idiopathic or heritable pulmonary arterial hypertension (PAH) compared to PAH associated with connective tissue diseaseInternational Journal of Cardiology, 2017
- Clinical Pharmacokinetics and Pharmacodynamics of the Endothelin Receptor Antagonist MacitentanClinical Pharmacokinetics, 2015
- Pulmonary hypertension related to left heart disease: Insight from a wireless implantable hemodynamic monitorThe Journal of Heart and Lung Transplantation, 2015
- Pulmonary Hypertension due to Lung Disease and/or HypoxiaClinics in Chest Medicine, 2013
- Pulmonary Hypertension Due to Left Heart DiseasesJACC, 2013
- Tadalafil for the Treatment of Pulmonary Arterial HypertensionJACC, 2012
- CHAMPION∗ Trial Rationale and Design: The Long-Term Safety and Clinical Efficacy of a Wireless Pulmonary Artery Pressure Monitoring SystemJournal of Cardiac Failure, 2011
- Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertensionJACC, 2004